Abstract
Campylobacter jejuni, a major foodborne human pathogen, has become increasingly resistant to fluoroquinolone (FQ) antimicrobials. By using clonally related isolates and genetically defined mutants, we determined the fitness of FQ-resistant Campylobacter in chicken (a natural host and a major reservoir for C. jejuni) in the absence of antibiotic selection pressure. When monoinoculated into the host, FQ-resistant and FQ-susceptible Campylobacter displayed similar levels of colonization and persistence in the absence of FQ antimicrobials. The prolonged colonization in chickens did not result in loss of the FQ resistance and the resistance-conferring point mutation (C257 → T) in the gyrA gene. Strikingly, when coinoculated into chickens, the FQ-resistant Campylobacter isolates outcompeted the majority of the FQ-susceptible strains, indicating that the resistant Campylobacter was biologically fit in the chicken host. The fitness advantage was not due to compensatory mutations in the genes targeted by FQ and was linked directly to the single point mutation in gyrA, which confers on Campylobacter a high-level resistance to FQ antimicrobials. In certain genetic backgrounds, the same point mutation entailed a biological cost on Campylobacter, as evidenced by its inability to compete with the FQ-susceptible Campylobacter. These findings provide a previously undescribed demonstration of the profound effect of a resistance-conferring point mutation in gyrA on the fitness of a major foodborne pathogen in its natural host and suggest that the rapid emergence of FQ-resistant Campylobacter on a worldwide scale may be attributable partly to the enhanced fitness of the FQ-resistant isolates.
Keywords: colonization, gyrA mutation, poultry
Antimicrobial resistance in bacterial pathogens has become a serious threat to public health. There is a general notion that the acquisition of drug resistance, particularly the resistance mediated by chromosomal mutations, entails a biological cost for pathogens, resulting in reduced fitness in the absence of antibiotic selection pressure (1, 2). However, evidence has accumulated that in vivo-selected or clinically derived isolates may develop compensatory mutations that reduce the fitness cost associated with antimicrobial resistance (3–7). Different environments (in vitro vs. in vivo) may select for different compensatory mutations and varied levels of restoration of fitness (8). Even without compensatory mutations, drug-resistant mutants may show little or no fitness cost (9). One important finding revealed by previous studies is that clinically derived drug-resistant isolates display diverse fitness changes, with some showing a biological cost and others showing no cost or even enhanced fitness (4, 10). The retention of ecological fitness in resistant pathogens creates a significant barrier for the elimination of resistant organisms by natural selection.
Campylobacter jejuni, a Gram-negative microaerobic bacterium, is a common causative agent of human enterocolitis (11). For antibiotic treatment of campylobacteriosis, erythromycin and fluoroquinolone (FQ) are the drugs of choice (12). However, Campylobacter has become increasingly resistant to FQ antimicrobials. Although FQ-resistant (FQR) Campylobacter occurs in clinical settings (13, 14), poultry are considered a significant source of FQR Campylobacter, because FQ antimicrobials have been used for the production of meat chickens, and the majority of domestically acquired cases of human campylobacteriosis result from consumption of undercooked chicken or food contaminated by raw chicken (11, 15). Therefore, reducing the occurrence and spread of FQR Campylobacter in poultry is considered an important step in the control of foodborne campylobacteriosis. Although it is known that FQR mutants rapidly occur during treatment with FQ antimicrobials (13, 16, 17), it is unclear whether the selected resistant Campylobacter is able to persist and compete with FQ-susceptible (FQS) Campylobacter in the absence of antibiotic selection pressure.
Campylobacter resistance to FQ antimicrobials is conferred by point mutations in the gyrA gene and the function of the multidrug efflux pump CmeABC (12, 16, 18). gyrA encodes the A subunit of DNA gyrase, which is a key enzyme involved in DNA replication and transcription (19). Resistance-conferring mutations in gyrA render the enzyme unsusceptible to the action of FQ antimicrobials. Acquisition of high-level FQ resistance in Campylobacter does not require stepwise accumulation of point mutations in gyrA. Instead, a single point mutation in gyrA can create clinically relevant levels of resistance to FQ antimicrobials (16, 20–22). Specific mutations at positions T86, D90, and A70 in GyrA were linked to FQ resistance in C. jejuni (12, 16, 22). Specifically, the T86I change [mediated by the C257 → T (C257T) mutation in the gene] is the most commonly observed mutation in FQR Campylobacter isolates and has been associated with high-level [ciprofloxacin minimal inhibitory concentration (MIC) ≥ 16 μg/ml] resistance to FQ, whereas the D90N and T86K mutations are less common and are associated with intermediate-level FQ resistance (16, 20–22). No mutations in gyrB have been associated with FQ resistance in Campylobacter (18, 23, 24), and the lack of parC (16, 18, 23–26) in Campylobacter has excluded the role of parC mutations in Campylobacter resistance to FQ antimicrobials. Although the function of multidrug efflux pump CmeABC is essential for FQ resistance, overexpression of cmeABC is not observed in FQR isolates (16).
The simplicity of the FQ resistance mechanism (single-step point mutations in gyrA) in Campylobacter and the easy access to its natural host (chicken) have provided an ideal system to address the impact of resistance-conferring mutations on the ecological fitness of antimicrobial-resistant pathogens. Understanding the fitness of FQR Campylobacter in its natural host will help us to determine whether the resistant pathogen is able to transmit and persist in the absence of antibiotic selection pressure, which will be useful for predicting and preventing the spread of FQR Campylobacter in animal reservoirs. Toward this end, we determined the fitness of FQR Campylobacter in chickens by using in vivo-derived clonally related isolates and isogenic mutants. It was revealed that the in vivo-derived FQR Campylobacter isolates outcompeted the majority of their clonally related FQS Campylobacter in the absence of antibiotic selection pressure, and the enhanced fitness in the resistant mutants was directly linked to the C257T mutation in the gyrA gene. These findings indicate that the single point mutation not only confers a high-level resistance to FQ antimicrobials but also modulates the in vivo fitness of Campylobacter.
Materials and Methods
Bacterial Strains and Culture Conditions. The C. jejuni strains used in this study are listed in Table 1. The parent strain S3B originally was isolated from chicken feces by this laboratory and is sensitive to FQ antimicrobials (ciprofloxacin MIC = 0.125 μg/ml). In a previous study (16) conducted to determine the emergence of FQR Campylobacter in chickens in response to the treatment with enrofloxacin, S3B was inoculated into several groups of chickens, some of which were treated subsequently with enrofloxacin, whereas others remained untreated as controls. Series of Campylobacter isolates were collected from the treated or nontreated chickens. Some of the isolates were used for the pairwise competitions conducted in this study (Table 1). The selected isolates on the same day after inoculation (DAI) were from different chickens. The Campylobacter strains were grown routinely in Mueller–Hinton (MH) broth or on MH agar plates at 42°C under microaerophilic conditions. When needed, the culture medium was supplemented with ciprofloxacin (4 μg/ml).
Table 1. Characteristics of Campylobacter strains used.
| Isolation date
|
||||
|---|---|---|---|---|
| Strains | DAI | DIQT | Cipro MIC, μg/ml | Mutation in gyrA |
| S3B | 0.125 | None | ||
| FQS* | ||||
| 62101S1 | 5 | N/T | 0.125 | None |
| 62101S2 | 5 | N/T | 0.125 | None |
| 62301S1 | 7 | N/T | 0.125 | None |
| 62301S2 | 7 | N/T | 0.125 | None |
| 62501S4 | 9 | N/T | 0.125 | None |
| 62501S5 | 9 | N/T | 0.125 | None |
| 70201S1 | 16 | N/T | 0.125 | None |
| 70201S16 | 16 | N/T | 0.125 | None |
| FQR† | ||||
| 62101R26 | 5 | 1 | >32 | C257T |
| 62101R31 | 5 | 3 | >32 | C257T |
| 62301R33 | 7 | 5 | >32 | C257T |
| 62301R38 | 7 | 5 | >32 | C257T |
| 62501R31 | 9 | 7 | >32 | C257T |
| 62501R32 | 9 | 7 | >32 | C257T |
| 70201R31 | 16 | 14 | >32 | C257T |
| 70201R35 | 16 | 14 | >32 | C257T |
| Defined mutants | ||||
| 62101S1R1‡ | >32 | C257T | ||
| 62301S2R1§ | >32 | C257T | ||
| 62301S2R2§ | >32 | C257T | ||
| 62301S2R3¶ | >32 | C257T | ||
DAI, DAI with strain S3B; DIQT, days after initiation of quinolone (enrofloxacin) treatment; Cipro, ciprofloxacin; N/T, not treated with enrofloxacin.
S3B derivatives isolated at different DAI from the control group of chickens inoculated with S3B, but not treated with enrofloxacin
S3B derivatives isolated at different DAI from the group of chickens inoculated with S3B and then treated with 50 ppm enrofloxacin, which was initiated at DAI 4 and continued until DAI 8
62101S1 transformed with the PCR product of gyrA containing the C257T mutation
62301S2 transformed with the PCR product of gyrA containing the C257T mutation
62301S2 transformed with the genomic DNA of 62301R33
PCR and Construction of Genetically Defined Mutants. PCR was used to amplify different regions of gyrA and gyrB (see Table 2, which is published as supporting information on the PNAS web site, for primer sequences) from various isolates. Natural transformation was used to generate genetically defined mutants containing the C257T mutation in gyrA. Briefly, the gyrA sequence containing the specific C257T mutation was amplified by PCR from isolates 62101R26 or 62301R33 by using primers GyrAF1 and GyrAR1 (Table 2). The PCR products containing the C257T T mutation were used to transform 62101S1 and 62301S2. In addition, the genomic DNA purified from 62301R33 (containing the C257T mutation in gyrA) also was used to transform 62301S2. Natural transformation was performed as described by Wang and Taylor (27) by using 3 μg of donor DNA (PCR products or genomic DNA). Transformants were selected by plating on MH plates supplemented with ciprofloxacin (4 μg/ml). Multiple transformants were obtained from each transformation, and representative clones including 62101S1R1, 62301S2R1, 62301S2R2, and 62301S2R3 (Table 1) were used in pairwise competition experiments. The gyrA and gyrB genes in the transformants used for the in vivo competitions were fully sequenced, confirming the presence of the C257T mutation in gyrA and the lack of any mutations in gyrB.
In Vivo Colonization and Persistence of Campylobacter. Specific pathogen-free White Leghorns were used to determine the colonization and persistence of different Campylobacter strains in the absence of antibiotic selection pressure. The birds were hatched in the specific pathogen-free chicken facility of the Food Animal Health Research Program of Ohio State University. Before use, all chickens were screened for Campylobacter by culturing cloacal swabs using MH agar plates containing Campylobacter-specific growth supplements and selective agents (Oxoid, Basingstoke, U.K.). No Campylobacter was detected in any of the birds before inoculation. Groups I (n = 18) and II (n = 18) were inoculated with isolate 62301R33 or S3B, respectively, at a dose of 107 colony-forming units (cfu) per chicken via oral gavage. Nonmedicated feed was given to the chickens ad libitum. FQ antimicrobials are not approved for use in feed additives in the U.S., and the feed extracts did not affect the growth rate of FQS or FQR Campylobacter in culture medium (data not shown). After inoculation, fecal samples were collected from each bird by means of cloacal swabs at different time points. Total Campylobacter colonies and FQR colonies in each sample were determined by using the Campylobacter selective plates and ciprofloxacin-containing (4 μg/ml) plates, respectively, as described in ref. 16.
In Vivo Competition. Newly hatched broiler chickens were obtained from commercial hatcheries. The chickens were tested negative for Campylobacter by culturing cloacal swabs before use. Seven to 10 chickens were used for each group. For competition experiments, each pair of Campylobacter isolates were grown separately in MH broth for 48 h under microaerophilic conditions and mixed in various ratios before given to chickens. The actual cfu in each inoculation mixture was determined by plating on MH agar plates (for total cfu) and MH agar plates with 4 μg/ml of ciprofloxacin (for FQR cfu). Each chicken received 100 μl of the mixture with a cell density of ≈107 cfu via oral gavage. Control groups were monoinoculated with either a FQR or FQS isolate. After inoculation, cloacal swabs were collected from the chickens at different intervals for culturing Campylobacter. As described above, each fecal suspension was serially diluted in MH broth and plated simultaneously onto two different types of culture media: conventional Campylobacter selective plates for recovering the total Campylobacter colonies and the selective MH plates supplemented with 4.0 μg/ml ciprofloxacin for recovering FQR Campylobacter colonies. Competition index (CI) was calculated as described by Khachatryan et al. (28) using the following formula: CI = (X - Y)/(X + Y), where X is the number of FQR colonies and Y is the number of FQS colonies. A positive CI value indicates that the FQR strain is more fit than the FQS population, whereas a negative CI value indicates that the FQS strain is more fit than the FQR population. When the CI is close to 1 or -1, it shows the dominance by FQR Campylobacter or FQS Campylobacter, respectively. Within a group, the CI values of individual birds across time points were used to test the null hypothesis (CI = 0) that there was no difference between the competing populations by using Student's t test. Repeated-measures ANOVA was used to compare the differences in CI values across groups. To confirm the results from the differential plating, 10–15 Campylobacter colonies were selected randomly for each group from the conventional selective plates (no ciprofloxacin) at each sampling time and tested for antibiotic susceptibility with Etest strips (AB Biodisk, Solna, Sweden). The selected colonies also were used for pulsed-field gel electrophoresis, which was performed according to procedures described in ref. 29.
Antimicrobial Susceptibility Test. The MIC of ciprofloxacin was determined by using Etest strips (AB Biodisk) as described in the manufacturer's instructions and in ref. 16. The FQS S3B isolate with a ciprofloxacin MIC of 0.125 μg/ml was used as an internal control for testing the isolates obtained from the chickens. The detection limit of the Etest for ciprofloxacin was 32 μg/ml. The MIC of cholic acid was measured by using a broth macrodilution method as described in ref. 30.
GenBank Accession Nos. The assigned GenBank accession nos. for gyrA and gyrB in strain S3B are AY196924 and AY621065, respectively.
Results
Characteristics of FQRCampylobacter. As determined by pulsed-field gel electrophoresis using kpnI- or SmaI-digested genomic DNA, the isolates used for pairwise competitions in this study all showed a genetic fingerprint identical to that of S3B (see Fig. 3, which is published as supporting information on the PNAS web site). Except for the C257T mutation (resulting in the T86I change) in the gyrA gene, no other mutations were detected in gyrA and gyrB of the FQR isolates. These findings plus the fact that Campylobacter lacks parC/parE suggested that no compensatory mutations occurred in the genes targeted by FQ antimicrobials in the FQR isolates. Compared with the clonally related or isogenic FQS Campylobacter, the FQR isolates did not show any growth defect or enhancement when separately cultured in MH broth with no added antibiotics (data not shown), indicating that the acquisition of FQ resistance in Campylobacter did not change its growth rate in culture medium. This finding was consistent with a previous observation made with in vitro-selected spontaneous FQR mutants of C. jejuni UA535 (20). Because motility is a key factor for Campylobacter colonization of chickens (31), we compared the motility of various Campylobacter isolates by using 0.4% Bacto agar (Difco). The FQR and FQS isolates were equally motile under the conditions used in this study (data not shown). Because the multidrug efflux pump CmeABC is essential for in vivo adaptation by mediating bile resistance in the intestinal tract (32), we also determined the expression level of CmeABC in the Campylobacter isolates. Immunoblotting indicated that the FQS and FQR isolates produced similar amounts of CmeABC proteins when grown in MH broth with no added antibiotics (data not shown). The MIC of cholic acid was also the same for both FQR and FQS Campylobacter. These observations indicated that the acquisition of FQ resistance did not cause obvious changes in the genotypic and phenotypic characteristics of Campylobacter when assayed in vitro.
In Vivo Persistence of FQRCampylobacter in the Absence of Antibiotic Selection Pressure. To determine whether FQR Campylobacter was able to colonize and persist in chicken (a natural host for Campylobacter) in the absence of antibiotic selection pressure, specific pathogen-free chickens were infected with either 62301R33 or S3B. After the inoculation, the chickens were quickly colonized by the strains. The colonization maintained at a high level from DAI 4–31 in both groups and then decreased gradually, with only two or three chickens positive for Campylobacter at the end of the experiment (Fig. 1A). The number of Campylobacter shed in feces also showed similar trends between the two groups (see Fig. 4, which is published as supporting information on the PNAS web site), ranging from as high as 108 cfu/g of feces between DAI 4–31 to 0–105 cfu/g of feces at the end of the experiment. Both differential plating and testing of individual colonies with Etest showed that all of the isolates from the group inoculated with 62301R33 were FQR (ciprofloxacin MIC > 32 μg/ml), and all of the isolates from the group inoculated with S3B were FQS (ciprofloxacin MIC = 0.125 μg/ml; Fig. 1B). Sequencing of the gyrA gene in the representative isolates collected from the group inoculated with 62301R33 revealed the same C257T mutation in all of the isolates. Pulsed-field gel electrophoresis analysis of the genomic DNA of the isolates showed a macrorestriction profile identical to that of 62301R33. These findings indicated that FQR Campylobacter colonized the chicken host efficiently and did not lose the gyrA mutation and its associated resistance to FQ for a prolonged period in the absence of antimicrobial selection pressure.
Fig. 1.
Colonization and persistence of FQR Campylobacter in the chicken host. (A) The number of chickens colonized with Campylobacter in each group (n = 18). Each data point represents the percentage of chickens colonized at each sampling time. The detection limit of the plating method is 100 cfu per g of fecal contents. (B) The resistance rates of Campylobacter isolated from each group. Ten to 15 isolates from each group at each sampling time were randomly selected and tested with ciprofloxacin Etest strips. MICs of ≥4.0 μg/ml are regarded as resistant.
In Vivo Competition. To determine whether FQR Campylobacter was ecologically fit in vivo, we first compared the in vivo derived FQR isolates 62301R33 and 62301R38 with the parent strain S3B by using pairwise competitions. After inoculation with either a single isolate or mixed populations, all of the groups were colonized by Campylobacter within 3 days (Fig. 2 A and B). No apparent differences in the colonization rate (the number of chickens colonized and the number of Campylobacter shed in feces) were observed among the groups, regardless of the FQ-resistance profile of the inoculum. Differential plating by using ciprofloxacin-containing plates showed that the group inoculated with S3B alone shed homogeneous FQS Campylobacter, whereas the groups inoculated with 62301R33 or 62301R38 shed homogeneous FQR Campylobacter during the entire course of the experiment. However, in the groups inoculated with mixtures of S3B/62301R33 or S3B/62301R38, the FQR population outcompeted the FQS Campylobacter (P < 0.001). The two groups for each pair of isolates yielded the same results regardless of the initial ratios (27–67% of FQR Campylobacter) of the two populations in the inoculum (Fig. 2 A and B). Once becoming dominant, the resistant population persisted in the chickens until the end of the experiments, which lasted for 42–46 days. Testing of randomly selected Campylobacter colonies (10 colonies per group per time point) by using Etest confirmed the results of differential plating. Together, these findings demonstrated that when coinoculated into chickens, the FQR Campylobacter outcompeted the FQS parent strain and quickly became the dominant population in the chickens.
Fig. 2.
Pairwise competition between FQR and FQS Campylobacter in the chicken host. Each data point represents the mean CI ± SE. Some SEs are smaller than the symbols. Seven to 10 birds were used in each group.
To further examine the fitness of FQR Campylobacter, a series of clonally related isolates derived from S3B-inoculated chickens were used for pairwise competition experiments (Table 1 and Fig. 2C). Each of the pairs contained a FQR and a FQS isolate, which were collected from the same experimental study at the same sampling time point (Table 1). All of these isolates were cultured fewer than three passages in MH broth before being used for the in vivo competition experiments. Among the eight pairs of isolates, FQR Campylobacter outcompeted the FQS population (P < 0.01) in six (62301S2/62301R33 and 62301S1/62301R38, collected at DAI 7; 62501S4/62501R31 and 62501S5/62501R32, collected at DAI 9; and 70201S1/70201R31 and 70201S16/70201R35, collected at DAI 16) of the pairs, whereas the FQS Campylobacter outcompeted FQR (P < 0.001) in the two pairs (62101S1/62101R31 and 62101S2/62101R26) of isolates collected at DAI 5. The CI values of the groups inoculated with 62101S1/62101R31 or 62101S2/62101R26 were significantly different from the CI values of the groups inoculated with other pairs (P < 0.001). Representative results with four of the pairs were shown in Fig. 2C. Independent replication experiments by using pair 62301S2/62301R33 or 62101S1/62101R31 further confirmed the competition outcomes. Within each pair, the dominance by the “winner” population happened within 3 days after the inoculation (Fig. 2C), suggesting that the competition occurred quickly in the infected birds. Together, these results indicated the six FQR isolates collected at DAI 7, 9, and 16 were biologically more fit than their clonally related FQS populations when coinoculated into chickens, whereas the two FQR isolates derived at DAI 5 could not compete with the FQS isolates derived from the same DAI.
The different competition outcomes between the Campylobacter isolates collected at DAI 5 and those collected at DAI 7, 9, and 16 might be due to the appearance of compensatory mutations in the later FQR isolates or subtle genetic differences between the FQS isolates collected at different time points. To test which possibility was most likely, we conducted the exchange of clinical isolates in pairwise competitions in chickens. If fitness-enhancing compensatory mutations had occurred in the later FQR isolates, we expected that 62301R33 would be able to compete with 62101S1. As shown in Fig. 2D, when 62301R33 (collected at DAI 7) was paired with 62101S1 (collected at DAI 5), the resistant population could not compete with the sensitive isolate (P < 0.01), although the same FQR isolate outcompeted the FQS isolate 62301S2 (Fig. 2C). Conversely, when 62101R31 was paired with 62301S2, the resistant isolate showed a clear fitness advantage (P < 0.001; Fig. 2D), even though 62101R31 was unable to compete with 62101S1 (Fig. 2C). This finding demonstrated that the FQR isolates collected at DAI 5 and 7 showed the same phenotype in chickens, which did not support the hypothesis that compensatory mutations had occurred in the later FQR isolates. This observation also suggested that the FQS isolates collected at DAI 5 and 7 might have subtle genetic differences, which could influence the outcomes of the competition between FQR and FQS Campylobacter.
To determine whether in vitro passage could affect the in vivo competition, isolates 62301S2 and 62301R33 were subjected to subculture in MH broth with no added antibiotics for 10 consecutive passages (≈160 generations). Then, the two isolates were mixed and inoculated into chickens (10 chickens per group). Again, 62301R33 outcompeted 62301S2 in the inoculated birds (P < 0.001). No significant differences (P > 0.05) were observed between the CI values of the group inoculated with the low-passage mixture and those of the group inoculated with the high-passage mixture, indicating that the limited in vitro passage did not change the outcome of the in vivo competition.
The gyrA Mutation Is Directly Linked to the in Vivo Fitness Change. To determine whether the fitness changes observed with the FQR isolates was due to the resistance-conferring gyrA mutation, the specific C257T mutation was introduced into 62101S1 and 62301S2 by using natural transformation to create genetically defined mutants (Table 1). These isogenic mutants were paired with the recipient strains for pairwise competition in chickens. When 62301S2R1 was paired with 62301S2, it rapidly outcompeted 62301S2 (P < 0.001; Fig. 2D) in two independent experiments. Furthermore, two additional isogenic mutants, 62301S2R2 and 62301S2R3, which were obtained from independent transformation experiments, also outcompeted 62301S2 (P < 0.001), indicating that the C257T mutation in gyrA was responsible for the fitness enhancement in the FQR isolates. There was no significant difference (P > 0.05) between the CI values of the groups inoculated with the isogenic pairs and the CI values of the group inoculated with 62301S2/62301R33, further suggesting that compensatory mutation was not involved in the competition of 62301R33 with 62301S2. When 62101S1R1 (an isogenic transformant of 62101S1) was paired with 62101S1, the FQR population was outcompeted by the FQS population (P < 0.001; Fig. 2D), indicating that introduction of the C257T mutation into the 62101S1 background reduced the in vivo fitness of the isolate. These results directly linked the fitness changes in the FQR isolates to the gyrA mutation and highlight the diverse effect of the mutation on Campylobacter fitness in different genetic backgrounds.
Discussion
This work represents the first report, to our knowledge, that documents the profound effect of a resistance-conferring mutation in gyrA on the fitness of FQR foodborne pathogens in animal reservoirs. Traditionally, studies assessing the fitness of drug-resistant pathogens mainly were conducted in vitro by using culture media, and only a few were performed in vivo by using animal models (4, 8, 28, 33, 34). Because the results from in vitro competition experiments do not necessarily reflect the outcomes of in vivo competition (4, 34), assessing the impact of antibiotic resistance on fitness should be ideally performed in the natural host of a pathogen. In this study, we examined the persistence and ecological fitness of FQR Campylobacter in chickens in the absence of selection pressure by using clonally related isolates and genetically defined mutants. The results clearly indicate that acquisition of FQ resistance in Campylobacter does not impair its colonization and persistence in chickens in the absence of antibiotic selection pressure (Fig. 1). Prolonged colonization in vivo did not result in the reversion or loss of the specific gyrA mutation (C257T), indicating that the resistance-conferring mutation can be stably maintained in the chicken host. This finding is consistent with the report that FQR Campylobacter was present in chicken flocks with no history of usage of FQ antimicrobials (35). Because the production cycle for broiler chickens is typically 6–7 weeks, findings from this study suggest that, once present in a flock, FQR Campylobacter will be able to stay in the flock until the slaughter age, potentially contaminating the chicken carcasses in processing plants.
As determined by pairwise competition experiments, the in vivo-derived FQR isolates outcompeted the parent strain and the majority of their clonally related FQS populations (Fig. 2 A–C). The enhanced fitness in FQR Campylobacter cannot be explained by compensatory mutations but is directly linked to the resistance-conferring mutation in gyrA. This conclusion is based on the following facts: (i) the FQR isolates had no compensatory mutations in GyrA and GyrB, which are the targets of FQ antimicrobials; (ii) exchange of FQR isolates collected at different time points did not change the outcome of the competitions (Fig. 2D); and (iii) introduction of the specific gyrA mutation (C257T) into the FQS isolates by natural transformation reproduced the competition outcomes of the clonally related FQR isolates (Fig. 2D). Any compensatory mutations, if they had existed in the in vivo-derived FQR isolates, should be eliminated in the genetically defined mutants because they were constructed by using donor DNA that only contained the specific C257T mutation in gyrA. The fitness advantage in Campylobacter conferred by the gyrA mutation is in contrast to the fitness costs incurred from antimicrobial resistance in other bacteria, in which compensatory mutations within or outside of the target genes are often needed to partially restore their fitness (1, 5, 8, 34).
One interesting finding of this study is the diverse effect of the C257T mutation in gyrA on Campylobacter fitness. When the C257T mutation was introduced into the 62101S1 background, it incurred a biological cost because the isogenic transformant (62101S1R1) was outcompeted by 62101S1 (Fig. 2D). In contrast, the same mutation enhanced Campylobacter fitness in the 62301S2 background. Isolates 62101S1 and 62301S2 were clonally related and obtained from the same group of chickens at DAI 5 and 7, respectively, after inoculation with S3B (16). Although they had identical gyrA and gyrB sequences and did not show any apparent differences as determined by pulsed-field gel electrophoresis, there might be some subtle genetic dissimilarities in the two FQS isolates, affecting the outcome of the competition. At this stage, it is unclear what the differences are and how the differences occurred in the chickens. Nevertheless, findings from this study suggest that, depending on the genetic background of the recipient strain, the C257T mutation can either enhance or reduce the fitness of Campylobacter in the chicken host.
The exact mechanisms involved in the competition in chickens are unknown. It should be pointed out that when separately inoculated into chickens at a dose of 107 cfu per bird, FQR and FQS Campylobacter showed similar levels of colonization and persistence in the host (Figs. 1 and 2). This observation indicates that, without competition, FQS and FQR Campylobacter are equally capable of colonizing chickens. When coinoculated into chickens at the same time, the two populations tended to exclude each other, resulting in the dominance of either population (Fig. 2). The outcompetition of one by another may not be attributed to differences in growth rates, cell motility, or CmeABC expression. In addition, we measured the competence for natural transformation in 62101S2, 62101R26, 62301S2, and 62301R33. By using an independent selection marker (chloramphenicol resistance) inserted in C. jejuni genome as the donor DNA, we found that the four isolates had similar transformation frequencies (data not shown), indicating that the FQR and FQS Campylobacter were comparable in their ability to take up exogenous DNA and suggesting that the competition outcome is unlikely due to differences in genetic competence of the tested strains.
Regardless of the mechanism involved in the in vivo competition, it can be concluded that the observed fitness changes in Campylobacter likely are due to the effect of the C257T mutation in gyrA (Fig. 2D). DNA gyrase consists of two subunits (GyrA and GyrB) assembled into a functional A2B2 holoenzyme, which catalyzes ATP-dependent negative supercoiling of DNA and plays an important role in DNA replication, transcription, and recombination (19). FQ antimicrobials form a stable complex with the enzyme and trap the enzyme on DNA, inhibiting DNA replication and transcription. Many bacterial pathogens have developed resistance to FQ antimicrobials by acquiring point mutations in DNA gyrase (36). It has been known in Escherichia coli that resistance-conferring mutations in GyrA can affect the supercoiling activity of the enzyme (37). Because DNA supercoiling is important for gene expression, it is possible that certain resistance-associated mutations in DNA gyrase may affect the transcription and expression of multiple or a subset of genes, which may consequently affect the fitness of the resistant pathogen in the intestinal tract. It will be interesting to determine whether the single C257T point mutation affects DNA supercoiling and gene expression in Campylobacter and whether the altered gene expression influences Campylobacter fitness in vivo.
Spontaneous point mutations conferring FQ resistance occur in gyrA of Campylobacter at a frequency of ≈5 × 10-8 when cultured in conventional media (20). If this mutation rate also applies to the in vivo infection, the number of spontaneous FQR mutants in FQS-infected chickens would be too low to be detected by the direct-plating method, which has a detection limit of 100 cfu/g of feces. Even though the spontaneous mutant may have a fitness advantage, it is unlikely that a single mutant can compete with 108 FQS Campylobacter without the help of antibiotic selection pressure. It is possible that a “critical mass” is required for FQR Campylobacter to successfully compete with FQS Campylobacter in the absence of selection pressure. Findings from this study were obtained by using a simplified system (clonally related isolates or isogenic mutants directly inoculated into chickens) and should be interpreted in the context of the complex nature of Campylobacter colonization and transmission in animal reservoirs, which are affected by multiple factors including bacterial virulence determinants, environmental conditions, management practices, and host immune status. The interaction of the resistance-conferring mutation (C257T) in gyrA with other bacterial factors in influencing Campylobacter fitness and the ability of FQR Campylobacter to transmit under different conditions as well as in the presence of genetically diverse competing strains remain to be determined in future studies. Nevertheless, results from this study suggest that the fitness enhancement conferred by the single point mutation in GyrA of FQR Campylobacter may have helped the emergence and spread of FQR isolates on poultry farms and in clinical settings. This possibility is supported by the fact that the majority of FQR Campylobacter isolates derived from animal reservoirs or human patients bear the C257T mutation in gyrA (21, 38, 39). Our findings also suggest that FQR Campylobacter may be able to persist in the animal reservoirs even without the usage of FQ antimicrobials, highlighting the need for effective measures to control the emergence and spread of FQR Campylobacter.
Supplementary Material
Acknowledgments
We thank Pat McDermott for critical review of the manuscript. This work is supported by U.S. Department of Agriculture Grants 00-51110-02095 and 2003-35212-13316 and National Institutes of Health Grant DK063008.
Author contributions: Q.Z. designed research; N.L., S.P., O.S., and S.H. performed research; J.L. and L.M. contributed new reagents/analytic tools; N.L., S.P., and J.L. analyzed data; and N.L. and Q.Z. wrote the paper.
Abbreviations: cfu, colony-forming units; CI, competition index; DAI, days after inoculation; FQ, fluoroquinolone; FQR, FQ-resistant; FQS, FQ-susceptible; MH, Mueller–Hinton; MIC, minimal inhibitory concentration.
Data deposition: The sequences reported in this paper have been deposited in the GenBank database (accession nos. AY196924 and AY621065).
References
- 1.Andersson, D. I. & Levin, B. R. (1999) Curr. Opin. Microbiol. 2, 489-493. [DOI] [PubMed] [Google Scholar]
- 2.Levin, B. R., Perrot, V. & Walker, N. (2000) Genetics 154, 985-997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Bjorkman, J., Hughes, D. & Andersson, D. I. (1998) Proc. Natl. Acad. Sci. USA 95, 3949-3953. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bjorkholm, B., Sjolund, M., Falk, P. G., Berg, O. G., Engstrand, L. & Andersson, D. I. (2001) Proc. Natl. Acad. Sci. USA 98, 14607-14612. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Nagaev, I., Bjorkman, J., Andersson, D. I. & Hughes, D. (2001) Mol. Microbiol. 40, 433-439. [DOI] [PubMed] [Google Scholar]
- 6.Normark, B. H. & Normark, S. (2002) J. Intern. Med. 252, 91-106. [DOI] [PubMed] [Google Scholar]
- 7.Andersson, D. I. (2003) Curr. Opin. Microbiol. 6, 452-456. [DOI] [PubMed] [Google Scholar]
- 8.Bjorkman, J., Nagaev, I., Berg, O. G., Hughes, D. & Andersson, D. I. (2000) Science 287, 1479-1482. [DOI] [PubMed] [Google Scholar]
- 9.Sander, P., Springer, B., Prammananan, T., Sturmfels, A., Kappler, M., Pletschette, M. & Bottger, E. C. (2002) Antimicrob. Agents Chemother. 46, 1204-1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Gillespie, S. H., Billington, O. J., Breathnach, A. & McHugh, T. D. (2002) Microb. Drug Resistance 8, 273-279. [DOI] [PubMed] [Google Scholar]
- 11.Tauxe, R. V. (2002) Int. J. Food Microbiol. 78, 31-41. [DOI] [PubMed] [Google Scholar]
- 12.Engberg, J., Aarestrup, F. M., Taylor, D. E., Gerner-Smidt, P. & Nachamkin, I. (2001) Emerg. Infect. Dis. 7, 24-34. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Segreti, J., Gootz, T. D., Goodman, L. J., Parkhurst, G. W., Quinn, J. P., Martin, B. A. & Trenholme, G. M. (1992) J. Infect. Dis. 165, 667-670. [DOI] [PubMed] [Google Scholar]
- 14.Ellis-Pegler, R. B., Hyman, L. K., Ingram, R. J. & McCarthy, M. (1995) J. Antimicrob. Chemother. 36, 259-263. [DOI] [PubMed] [Google Scholar]
- 15.Kassenborg, H. D., Smith, K. E., Vugia, D. J., Rabatsky-Ehr, T., Bates, M. R., Carter, M. A., Dumas, N. B., Cassidy, M. P., Marano, N., Tauxe, R. V., et al. (2004) Clin. Infect. Dis. 38, Suppl. 3, S279-S284. [DOI] [PubMed] [Google Scholar]
- 16.Luo, N., Sahin, O., Lin, J., Michel, L. O. & Zhang, Q. (2003) Antimicrob. Agents Chemother. 47, 390-394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.McDermott, P. F., Bodeis, S. M., English, L. L., White, D. G., Walker, R. D., Zhao, S., Simjee, S. & Wagner, D. D. (2002) J. Infect. Dis. 185, 837-840. [DOI] [PubMed] [Google Scholar]
- 18.Bachoual, R., Ouabdesselam, S., Mory, F., Lascols, C., Soussy, C. J. & Tankovic, J. (2001) Microb. Drug Resist. 7, 257-261. [DOI] [PubMed] [Google Scholar]
- 19.Champoux, J. J. (2001) Annu. Rev. Biochem. 70, 369-413. [DOI] [PubMed] [Google Scholar]
- 20.Gootz, T. D. & Martin, B. A. (1991) Antimicrob. Agents Chemother. 35, 840-845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Ruiz, J., Goni, P., Marco, F., Gallardo, F., Mirelis, B., Jimenez De Anta, T. & Vila, J. (1998) Microbiol. Immunol. 42, 223-226. [DOI] [PubMed] [Google Scholar]
- 22.Wang, Y., Huang, W. M. & Taylor, D. E. (1993) Antimicrob. Agents Chemother. 37, 457-463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Payot, S., Cloeckaert, A. & Chaslus-Dancla, E. (2002) Microb. Drug Resist. 8, 335-343. [DOI] [PubMed] [Google Scholar]
- 24.Piddock, L. J., Ricci, V., Pumbwe, L., Everett, M. J. & Griggs, D. J. (2003) J. Antimicrob. Chemother. 51, 19-26. [DOI] [PubMed] [Google Scholar]
- 25.Parkhill, J., Wren, B. W., Mungall, K., Ketley, J. M., Churcher, C., Basham, D., Chillingworth, T., Davies, R. M., Feltwell, T., Holroyd, S., et al. (2000) Nature 403, 665-668. [DOI] [PubMed] [Google Scholar]
- 26.Cooper, R., Segal, H., Lastovica, A. J. & Elisha, B. G. (2002) J. Appl. Microbiol. 93, 241-249. [DOI] [PubMed] [Google Scholar]
- 27.Wang, Y. & Taylor, D. E. (1990) J. Bacteriol. 172, 949-955. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Khachatryan, A. R., Hancock, D. D., Besser, T. E. & Call, D. R. (2004) Appl. Environ. Microbiol. 70, 752-757. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Zhang, Q., Meitzler, J. C., Huang, S. & Morishita, T. (2000) Infect. Immun. 68, 5679-5689. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Lin, J., Michel, L. O. & Zhang, Q. (2002) Antimicrob. Agents Chemother. 46, 2124-2131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Nachamkin, I., Yang, X. H. & Stern, N. J. (1993) Appl. Environ. Microbiol. 59, 1269-1273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Lin, J., Sahin, O., Michel, L. O. & Zhang, Q. (2003) Infect. Immun. 71, 4250-4259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Gustafsson, I., Cars, O. & Andersson, D. I. (2003) J. Antimicrob. Chemother. 52, 258-263. [DOI] [PubMed] [Google Scholar]
- 34.Giraud, E., Cloeckaert, A., Baucheron, S., Mouline, C. & Chaslus-Dancla, E. (2003) J. Med. Microbiol. 52, 697-703. [DOI] [PubMed] [Google Scholar]
- 35.Pedersen, K. & Wedderkopp, A. (2003) J. Appl. Microbiol. 94, 111-119. [DOI] [PubMed] [Google Scholar]
- 36.Drlica, K. & Malik, M. (2003) Curr. Top. Med. Chem. 3, 249-282. [DOI] [PubMed] [Google Scholar]
- 37.Barnard, F. M. & Maxwell, A. (2001) Antimicrob. Agents Chemother. 45, 1994-2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Hakanen, A., Jalava, J., Kotilainen, P., Jousimies-Somer, H., Siitonen, A. & Huovinen, P. (2002) Antimicrob. Agents Chemother. 46, 2644-2647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Lucey, B., Cryan, B., O'Halloran, F., Wall, P. G., Buckley, T. & Fanning, S. (2002) Vet. Rec. 151, 317-320. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.


